Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations.

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.The pharmaceutical company, however,

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove sales. Despite losing patent protections, revenue rose 1% to $12.3 billion.